Pharmacists May Require Additional Training on Corticophobia in Atopic Dermatitis
Misinformation regarding the use of corticosteroids remains persistent and may have implications on patient care.
ICYMI: sBLA for Hyrimoz (Adalimumab-adaz) Approved as Interchangeable Biosimilar to Humira
Last week, the FDA approved an sBLA for Sandoz’s adalimumab-adaz in various strengths, including 10 mg/0.1 mL, 20 mg/0.2 mL, and 80 mg/0.8 mL.
FDA Organizations Issue Joint Paper on Responsible and Ethical Use of Artificial Intelligence in Medical Research
The paper was authored and issued by the FDA Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, Center for Devices and Radiological Health, and Office of Combination Products.
Progression-Free Survival of BRAF-Mutant Melanoma Improved by Combination Therapy
A combined treatment regimen of encorafenib and binimetinib led to improved progression-free survival, overall response rate, and tolerability in patients with advanced BRAF-mutant melanoma.